Cambridge Healthtech Institute’s 22nd Annual

Cell Culture & Upstream Processing

Optimized Media. Higher Titers. Smarter Processes.

August 12 - 13, 2026 ALL TIMES EDT

The Cell Culture and Upstream Processing conference delivers in-depth scientific and engineering insight into the technologies shaping today’s biomanufacturing. The program explores advanced media development for complex modalities, intensified and perfusion-based processes, and strategies for scaling biologics beyond traditional mAbs. Attendees will also gain practical guidance on real-time process monitoring, digital twins, predictive modeling, and integration of up- and downstream processing. This meeting equips scientists and engineers with the tools to drive efficiency, ensure product quality, and accelerate next-generation manufacturing innovation.

Wednesday, August 12

12:20 pmRefreshment Break in the Exhibit Hall with Poster Viewing

12:30 pmRegistration Open

SCALING UP STRATEGIES & CHALLENGES

1:00 pm

Chairperson's Remarks

Stefano Menegatti, PhD, Professor, Chemical and Biomolecular Engineering, North Carolina State University

1:05 pm

KEYNOTE PRESENTATION: Converting Low-Seed Processes to Intensified Fed-Batch Processes through Smart Media Design and PAT Controls

Sarwat Khattak, PhD, Head of Cell Culture and Cell Line Development, Biogen

Intensified fed-batch and high-density seed strategies are increasingly adopted to improve upstream efficiency while minimizing operational complexity. This presentation demonstrates how N-1 perfusion, smart media design, and PAT-enabled control can be combined to convert low-seed platform processes into intensified fed-batch processes. Across multiple programs, this strategy achieved ~2X improvements in space–time yield and ~30% shorter production durations, while maintaining product quality and avoiding full perfusion at production scale.

1:35 pm

Optimizing Scale-Up Strategies for Monoclonal Antibody Production in a Government Facility

Jishna Ganguly, MSc. Senior Scientist, Walter Reed Army Institute of Research (WRAIR)

Stasya Zarling, Director, Pilot Bioproduction Facility, Walter Reed Army Institute of Research

Scaling up monoclonal antibody (mAb) production from bench-scale to pilot-scale bioreactors is a complex process that requires optimizing operating parameters to maintain consistent hydrodynamic and mass-transport conditions. This talk highlights process characterization at bench-scale bioreactors and scale-up strategies to 40L or larger GMP production, focusing on ensuring regulatory compliance and product quality within a government laboratory setting.

2:05 pm

Scaling Up TFF for Upstream Continuous Processing: Applications of Mechanistic Modeling

Ashna Dhingra, Bioprocess Technologies & Engineering, Senior Scientist, AstraZeneca

Tangential flow filtration (TFF) enables scalable CHO cell retention for perfusion culture; however, resulting filter fouling reduces product recovery. We present a first-principles model combining cell kinetics, fluid mechanics, and fouling dynamics to predict membrane performance and product-sieving profiles across scales and projects. Our predictive framework demonstrates how operational parameters and filter geometry influence product sieving while providing insights into fouling mechanisms, membrane efficiency, and flux distributions.

2:35 pm

(CANCELLED - Please attend an alternative concurrent session) Developing & Scaling-up Intensified Fed-Batch Processes

Jose M. Gomes, Senior Principal Scientist & Manager, Bioprocess R&D, Pfizer Inc.

This presentation covers the development and scale-up of intensified fed-batch processes, highlighting key strategies for increasing productivity and process consistency across manufacturing scales.

3:05 pm The Power of Data, Digitalization, and AI to Effectively Scale-Up Bioprocess Development

Erik Bierwagen, Biosciences Portfolio Lead, Biosciences, Dassault Systemes

Bioprocess development—especially scaling up—demands robust data tracking, management, search, and visualization to monitor runs, materials, recipes, and process versions. I’ll showcase BIOVIA’s current capabilities, enhanced by our Scientific AI, that enable effective scaling.

3:20 pm Cell Line Development and CloneSelection: Automated Workflow Solutions

Andrew Wu, Senior Application Scientist, Beckman Coulter Inc.

Cell line development remains a critical bottleneck in biotherapeutic development, requiring significant hands-on effort for clone screening, characterization, and process optimization. Advances in laboratory automation are enabling scientists to increase throughput, improve data quality, and accelerate timelines while reducing manual intervention. This presentation will highlight integrated workflow solutions that support cell line development from clone selection through process development. We will discuss how automated platforms such as the Cydem VT Automated Clone Screening System and Vi-CELL BLU Cell Viability Analyzer enable high-throughput clone evaluation, automated cell health monitoring, and scalable process development.

3:35 pmRefreshment Break in the Exhibit Hall with Poster Viewing

PLENARY KEYNOTE SESSION

4:20 pm

Chairperson's Remarks

Susan Hynes, Global Head of Quality, GSK

4:25 pm

The Correct Way to Bring Digitalization and AI into Biopharmaceutical Quality

Anthony R. Mire-Sluis, PhD, Senior Vice President, Global Quality, Gilead Sciences

Digitalizing quality systems and artificial intelligence could revolutionize the way we work in quality. However, it needs careful planning and execution to gain the maximum benefits to the business. Appropriate use cases, change management, training, and streamlining processes before you digitalize is essential—adding complexity just results in digital complexity. In addition, the implementation of AI must follow GxP principles in what is currently a vague regulatory framework.

4:55 pm

Fireside Chat with Audience Q&A

PANEL MODERATOR:

Susan Hynes, Global Head of Quality, GSK

PANELISTS:

Lynn Bottone, Senior Vice President, Quality Operations, Environment Health & Safety, Pfizer Inc.

Anthony R. Mire-Sluis, PhD, Senior Vice President, Global Quality, Gilead Sciences

5:15 pmNetworking Reception in the Exhibit Hall with Poster Viewing

6:15 pmClose of Day

Thursday, August 13

7:30 amRegistration and Morning Coffee

MIDSTREAM OPERATIONS: POSITIONING FOR DOWNSTREAM SUCCESS

8:00 am

Chairperson's Remarks

Sarwat Khattak, PhD, Head of Cell Culture and Cell Line Development, Biogen

8:05 am

Mid-Stream Bioprocessing of Gene Therapy Vectors: Setting the Stage for Successful Purification

Stefano Menegatti, PhD, Professor, Chemical and Biomolecular Engineering, North Carolina State University

Midstream bioprocessing critically determines the recovery and purity of gene therapy products. This presentation examines how midstream decisions (harvest timing, depth filtration, tangential-flow filtration) set the stage for successful purification. We discuss the impact of midstream processing on chromatographic operations and the resulting quality attributes of adeno-associated virus, lentivirus, and adenovirus. Leveraging process optimization frameworks, we demonstrate how midstream excellence enables robust purification workflows that ensure therapeutic efficacy and safety.

8:35 am

Optimization of the Harvest Process for AAV-Based Gene Therapy Manufacturing

Yixuan Ming, PhD, Downstream Process Development Scientist, Technology Development, Genentech Inc.

This study evaluates alternative nucleases/methods for the harvest of AAV vectors after upstream production. By analyzing the impact of various nucleases/methods under diverse conditions, we assessed process performance, product quality, and downstream Cost of Goods (CoG). Our findings provide critical insights for optimizing the harvest process, balancing robust process with economic efficiency in gene therapy manufacturing.

9:05 am

Optimizing an AAV Harvest Process Development of a Mixing Scale-Down Model for Enhanced Filtration Performance

Yaozhong Zhang, PhD, Principal Scientist, Purification Process Development, Genomic Medicine CMC, Sanofi Group

In Sanofi’s AAV manufacturing platform, the harvest process typically involves a flocculation step, where mixing plays a critical role. Developing a robust mixing scale‑down model is essential. Floc formation dynamics were characterized in real time using EasyViewer technology. The developed scale‑down model demonstrated excellent predictive performance. Implementation of the optimized flocculation conditions resulted in a two‑fold increase in depth filter throughput.

9:35 amCoffee Break in the Exhibit Hall with Poster Viewing

MENTORING MEET-UP

9:40 am

Mentoring Meet-Up: Creating and Fostering a Productive and Effective Mentor-Mentee Relationship

Sebastien Latapie, MBA, Partner, Avant Bio

Juergen Mairhofer, CEO & Co-Founder, enGenes Biotech GmbH

This meet-up is designed to connect scientists that are interested in becoming a mentor as well as junior scientists who are interested in being a mentee:

  • What it takes to be a mentor
  • Finding the right match
  • Goal of Mentoring is to provide support for professional career development and informal coaching
  • The Mentor: Mentee relationship: you get out of it what you put into it
  • Establishing boundaries and clear action items to make the most of the experience
  • How can having a mentor help you?
  • What kind of time commitment does being a mentee entail?
  • How many mentors do I need?​

IMPROVING CELL CULTURE PROCESSES AND MANUFACTURING

10:15 am

Increasing Cell Culture Process Robustness through Raw Material and Metabolic Understanding

Dana Motabar, PhD, Senior Scientist, Cell Culture Process Development, AbbVie Inc.

Consistency and robustness in cell-culture processes are critical for the reliable production of biologics. This presentation will showcase studies describing strategies applied to identify potential sources of variability—and strategies to mitigate them. To this end, we use a proactive risk-assessment approach to identify potential raw-material variability and apply data-driven mitigation strategies. Additionally, we use omics tools to unravel complex molecular interactions.

10:45 am

A Model-First Approach for Bioprocess Development: From Process Understanding to Prediction and Control

Bhanu Chandra Mulukutla, PhD, Research Fellow, Group Leader, Process Development, Pfizer Inc.

This presentation introduces mechanistic modeling frameworks developed to predict the complex dynamics of multispecific co-culture systems, providing a quantitative foundation for understanding and monitoring process behavior across varying conditions.

11:15 am

Harvest Process Characterization Case Study

Ricky Okafor, Associate Scientist, Upstream Process Development, Alexion Pharmaceuticals

Advances in cell culture have increased cell-culture densities and productivities but also elevated submicron particles, challenging the clarification step. Addressing this, a non-platform harvest process beyond typical centrifugation and depth-filtration was developed. Harvest process characterization was conducted to ensure process robustness and product quality consistency. This presentation describes the risk-based approach used to identify potential critical-parameters and the study performed to evaluate their harvest performance and product quality attribute impact.

11:45 am Accelerating Upstream Efficiency: At-Line Titer Monitoring - Lonza

Roger Connolly, Lead Scientist, Lonza Group

During cell line screening and upstream process development for monoclonal antibody production, the high volume of samples often requires trained analysts and hours or days of runtime, delaying critical trend analysis and forward process decision-making.

To solve this, Roger Connolly, of Lonza, demonstrates how they streamline bioprocessing through the HaLCon concentration analyzer for rapid, on-demand, at-line titer analysis of Fc-fusion proteins.

Also, by providing real-time data, such as daily product sieving monitoring throughout a perfusion process, this approach enables teams to detect bioreactor conditions early and establish a single, scalable platform for rapid titer analysis from benchtop through manufacturing.

12:15 pmTransition to Lunch

12:20 pm LUNCHEON PRESENTATION: Predicting Filtration Performance through Multiscale Modeling

Santosh Konangi, Applications Engineering, Senior Staff Engineer, Ansys part of Synopsys

This presentation introduces an end-to-end multiscale simulation framework that combines Synopsys Simpleware, Ansys Fluent, and Ansys Rocky to create image-based digital twins of filtration systems. Starting from micro-CT scans of filtration media, pore-scale transport and particle interactions are resolved within the membrane structure and linked to system-level models that predict pressure drop, permeability, fouling behavior, and overall cassette performance. A case study developed in collaboration with Pfizer demonstrates how the approach enables virtual evaluation of tangential flow filtration (TFF) systems across operating conditions, providing mechanistic insight into fouling dynamics and performance limitations. The workflow establishes a direct connection between membrane microstructure and process-scale outcomes, enabling faster design exploration, reduced experimental burden, and more informed decisions for filtration development and scale-up.

12:50 pmRefreshment Break in the Exhibit Hall with Last Chance for Poster Viewing

DIGITAL TWINS AND AI/ML STRATEGIES IN UPSTREAM PROCESSES

1:30 pm

Chairperson's Remarks 

Anastasia Nikolakopoulou, PhD, Principal Scientist, Data Sciences Process Modeling, Sanofi

1:35 pm

Cell Culture Digital Twins Enabling Efficient Scale-Up and Tech Transfer

Brooke Tam, PhD, USP Modeling Expert, Sanofi

Digital twins are valuable for efficiently transferring complex processes from the laboratory to manufacturing scale and ensuring consistent results at different manufacturing sites. Here, we discuss case studies in the application of cell culture digital twins to tech transfer programs and demonstrate how modeling has allowed us to meet aggressive timelines and better serve the patients who need our products.

2:05 pm

Smart Bioprocessing with PatroLab: Real-Time Monitoring, Simulation, and Control

Zhuangrong Huang, PhD, Director, Wuxi Biologics, formerly Senior Staff Engineer, Takeda Pharmaceuticals Co. Ltd.

This presentation highlights the PatroLab digital platform, which integrates process analytical technology (PAT), digital twins, and predictive process control for advanced bioprocessing. By combing Raman spectroscopy, mechanistic models, and machine learning, PatroLab enables real-time monitoring, simulation, forecasting, and dynamic process control. Case studies will demonstrate improved process consistency, scalable process development, reduced variability, and enhanced manufacturing efficiency.

2:35 pm

Digital Twins in Bioprocessing: Industrial Showcases for Biosimilar Development, Viral Vectors, Media Optimization, UF/DF, and End-to-End Process Control

Mark Duerkop, CEO, Novasign GmbH

This presentation explores how digital twins, combining mechanistic process understanding, AI, and process data, enable smarter, faster bioprocess development and control. Six industrial use cases demonstrate the value of digital twins: accelerated biosimilar development using PAT and glycan modeling; reduced experimental effort in viral vector process design; media optimization through time-resolved nutrient uptake prediction; UF/DF development guided by digital membrane and recovery modeling; scale-up informed by CFD-based reactor behavior; and fully integrated digital control of continuous bioprocesses sustained for over 30 days. Together, these examples show how digital twins streamline experimentation, enhance decision-making, and de-risk scale-up—unlocking end-to-end process insight from early development to production.

3:05 pm

An AI/ML-Powered Workflow for End-to-End Cell Line Development

Shalini Raj Unnikandam Veettil, PhD, Senior Scientist, Technology Development Strategy & Operations, Gilead Sciences Inc.

CLAIRE (Cell Line AI Recognition and Evaluation) streamlines clonal CHO cell line development by combining deep-learning image analysis with automated liquid handling. It supports automated monoclonality verification, quality assessment, colony quantification, and hit-pick list generation for liquid handlers. Integrated within a user interface and paired with Lynx automation, it enables a streamlined, end-to-end workflow that reduces manual effort and compresses development timelines to 36 days.

3:35 pmClose of Summit





No Agenda API URL configured.